vs
Side-by-side financial comparison of Net Lease Office Properties (NLOP) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $30.7M, roughly 1.9× Net Lease Office Properties). Net Lease Office Properties runs the higher net margin — -0.2% vs -83.0%, a 82.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 10.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -16.4%).
Net Lease Office Properties is a real estate investment entity focused on acquiring, owning, and operating high-quality single-tenant net lease office assets, primarily located across the United States. It delivers stable, long-term income streams to investors through its curated portfolio of commercial real estate holdings.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NLOP vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.7M | $57.3M |
| Net Profit | $-53.0K | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -0.2% | -82.2% |
| Net Margin | -0.2% | -83.0% |
| Revenue YoY | 10.9% | 36.9% |
| Net Profit YoY | 99.9% | -9.6% |
| EPS (diluted) | $-0.01 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.7M | $57.3M | ||
| Q3 25 | $29.8M | $51.3M | ||
| Q2 25 | $29.2M | $48.5M | ||
| Q1 25 | $29.2M | $32.7M | ||
| Q4 24 | $27.7M | $41.8M | ||
| Q3 24 | $31.5M | $33.3M | ||
| Q2 24 | $39.0M | $29.1M | ||
| Q1 24 | $44.0M | $26.0M |
| Q4 25 | $-53.0K | $-47.5M | ||
| Q3 25 | $-64.2M | $-52.9M | ||
| Q2 25 | $-81.5M | $-46.6M | ||
| Q1 25 | $492.0K | $-49.5M | ||
| Q4 24 | $-35.8M | $-43.3M | ||
| Q3 24 | $-40.3M | $-43.6M | ||
| Q2 24 | $12.5M | $-32.3M | ||
| Q1 24 | $-27.8M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -0.2% | -82.2% | ||
| Q3 25 | -215.2% | -102.6% | ||
| Q2 25 | -279.1% | -93.4% | ||
| Q1 25 | 2.0% | -143.7% | ||
| Q4 24 | -140.7% | -98.6% | ||
| Q3 24 | -126.4% | -132.0% | ||
| Q2 24 | 32.3% | -139.2% | ||
| Q1 24 | -62.7% | -538.7% |
| Q4 25 | -0.2% | -83.0% | ||
| Q3 25 | -215.4% | -103.1% | ||
| Q2 25 | -279.5% | -96.1% | ||
| Q1 25 | 1.7% | -151.4% | ||
| Q4 24 | -129.0% | -103.6% | ||
| Q3 24 | -128.0% | -131.2% | ||
| Q2 24 | 31.9% | -110.9% | ||
| Q1 24 | -63.3% | -544.4% |
| Q4 25 | $-0.01 | $-0.73 | ||
| Q3 25 | $-4.33 | $-0.82 | ||
| Q2 25 | $-5.50 | $-0.75 | ||
| Q1 25 | $0.03 | $-0.81 | ||
| Q4 24 | $-2.41 | $-0.71 | ||
| Q3 24 | $-2.73 | $-0.73 | ||
| Q2 24 | $0.84 | $-0.55 | ||
| Q1 24 | $-1.88 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $119.6M | $388.9M |
| Total DebtLower is stronger | $21.9M | — |
| Stockholders' EquityBook value | $293.9M | $139.1M |
| Total Assets | $453.4M | $480.2M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.6M | $388.9M | ||
| Q3 25 | $38.7M | $416.1M | ||
| Q2 25 | $54.1M | $291.0M | ||
| Q1 25 | $28.2M | $314.5M | ||
| Q4 24 | $25.1M | $320.6M | ||
| Q3 24 | $36.1M | $298.4M | ||
| Q2 24 | $36.1M | $319.1M | ||
| Q1 24 | $39.8M | $201.2M |
| Q4 25 | $21.9M | — | ||
| Q3 25 | $47.1M | — | ||
| Q2 25 | $117.2M | — | ||
| Q1 25 | $148.5M | — | ||
| Q4 24 | $169.2M | — | ||
| Q3 24 | $239.4M | — | ||
| Q2 24 | $327.4M | — | ||
| Q1 24 | $515.2M | — |
| Q4 25 | $293.9M | $139.1M | ||
| Q3 25 | $430.3M | $148.8M | ||
| Q2 25 | $500.0M | $-11.9M | ||
| Q1 25 | $582.1M | $18.9M | ||
| Q4 24 | $581.2M | $21.7M | ||
| Q3 24 | $621.9M | $11.2M | ||
| Q2 24 | $660.3M | $39.3M | ||
| Q1 24 | $647.2M | $61.6M |
| Q4 25 | $453.4M | $480.2M | ||
| Q3 25 | $522.6M | $506.9M | ||
| Q2 25 | $668.7M | $372.7M | ||
| Q1 25 | $784.1M | $386.7M | ||
| Q4 24 | $805.1M | $392.3M | ||
| Q3 24 | $919.9M | $363.6M | ||
| Q2 24 | $1.0B | $381.8M | ||
| Q1 24 | $1.2B | $258.7M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.80× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $64.1M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.1M | $-25.4M | ||
| Q3 25 | $16.3M | $-26.6M | ||
| Q2 25 | $11.7M | $-23.3M | ||
| Q1 25 | $14.1M | $-40.4M | ||
| Q4 24 | $71.9M | $-18.8M | ||
| Q3 24 | $20.3M | $-25.2M | ||
| Q2 24 | $14.7M | $-29.1M | ||
| Q1 24 | $26.4M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.70× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
